Medicare paid an estimated $380 million for organs that never went into Medicare patients because written rules clashed with federal law.
Story Snapshot
- A federal watchdog tied the overpayment to conflicting guidance and statute.
- Sample review found 55 organs billed that were not used in covered transplants, totaling $2.8 million.
- The estimate covers six years of payments to certified transplant centers.
- The Centers for Medicare and Medicaid Services pays separately for organ acquisition costs.
What the audit proved and why it matters
The Department of Health and Human Services Office of Inspector General reported that Medicare overpaid transplant centers by about $380 million from 2017 to 2022 for organs not transplanted into Medicare enrollees. The watchdog reached that figure by sampling cost reports and projecting the result to the full program. One sample detail stands out. Of 180 “Medicare usable” organs reviewed, 55 were either used for non-Medicare patients or never transplanted at all, yet Medicare still paid $2.8 million for their acquisition.
The Office of Inspector General did not call this fraud. It traced the payments to a conflict between the Centers for Medicare and Medicaid Services guidance and federal statutory limits. That framing matters. If centers followed the manual, they will say they complied. But taxpayers still lose when guidance drifts from law. The conservative test is simple: pay for what the law allows, no more. When rules get muddy, money leaks. Clear law and tight edits to guidance can stop it.
How the payment system allowed the mismatch
The Centers for Medicare and Medicaid Services pays transplant hospitals in two parts. One payment covers the surgery and care. Another payment reimburses “reasonable and necessary” costs to get the organ, such as testing and coordination. Guidance also tells centers how to count “Medicare usable” organs for cost-sharing across payers. The Office of Inspector General said those instructions sometimes told centers to count organs that went elsewhere, creating a mismatch with the statute’s limit to Medicare-covered transplants.
The audit’s spotlight on the definition of “Medicare usable” explains the ripple. If a center counts an organ under guidance but it is not used in a Medicare-covered transplant, Medicare can still end up with the bill. The sample shows that risk. The 55 questioned organs included some used in non-Medicare patients and some never transplanted at all, yet costs flowed to Medicare. That is not a paperwork nit. It is a design flaw that steers costs away from the right payer and onto seniors’ program.
The numbers, the limits, and what should change next
The $380 million figure is an estimate from a sample, not a full claim-by-claim tally. That does not let the system off the hook. Auditors use samples in Medicare all the time, and Congress accepts that practice. The size and clarity of the sample finding make the risk plain enough to act. The Centers for Medicare and Medicaid Services should revise its manuals to align with statute fast, publish a list of fixes, and direct contractors to reopen cost reports where allowed by law to recover funds.
Hospitals will likely argue they followed the book and planned budgets around it. Fair point on process, but the book must match the law. The right path is simple: clarify the definition of a reimbursable organ acquisition to those tied to Medicare-covered transplants, set bright-line examples, and require attestations on cost reports. Then report back on recoupments and prevent repeat leaks. That is stewardship, and seniors deserve nothing less.
The broader pattern and the accountability playbook
This case fits a larger pattern in Medicare. Complex rules, guidance updates, and contractor interpretations often outpace what the statute meant to fund. The Office of Inspector General flagged nationwide work on organ payments, so this is not a one-off review. Policymakers should use three levers now. First, demand a timeline from the Centers for Medicare and Medicaid Services to align guidance with statute. Second, require a reconciliation study on how much was already corrected at settlement. Third, publish center-level aggregates to focus local oversight.
Taxpayers have long memories when the bill hits home. Paying for organs that did not reach Medicare patients breaks public trust, no matter how it happened. The fix is not hard. Tight definitions, clean instructions, and real audits stop waste before it spreads. The Office of Inspector General lit the path. The Centers for Medicare and Medicaid Services should walk it, and Congress should make sure they do, with results reported in plain language and dollars returned where the law allows.
Sources:
zerohedge.com, yahoo.com, goodsurance.com, newsweek.com
